Results 121 to 130 of about 36,390 (302)
The accumulation and infiltration of eosinophils in airways is one of the most important characteristics of asthma, and is mediated partly by secretion of IL-5 from Th2 lymphocytes.
Weining Xiong +6 more
core
ABSTRACT Objective Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent inflammatory condition often associated with other type‐2 diseases. Dupilumab, a monoclonal antibody targeting IL‐4Rα, has revolutionized the treatment of severe CRSwNP.
Pietro Orlando +17 more
wiley +1 more source
Asthma exacerbations are acute worsening episodes in individuals with bronchial asthma, frequently necessitating emergency hospital care. Early differentiation between eosinophilic (≥150 eosinophils/mm3) and non-eosinophilic (
Nicolae Demenciuc +7 more
doaj +1 more source
Eosinophilic and Noneosinophilic Asthma [PDF]
Tara F, Carr +2 more
openaire +2 more sources
Inflammatory Shift in Chronic Rhinosinusitis Amidst Guangzhou's Urbanization (2000–2018)
ABSTRACT Background Chronic rhinosinusitis (CRS) exhibits temporal and geographic diversity in pathological endotypes with progressive eosinophilic infiltration, while the underlying causes remain unclear. Current pathological endotypes determination relies on mean cell count per high‐power field, requiring accuracy optimization.
Ning Kang +16 more
wiley +1 more source
Wang Chun Kwok, Julie Kwan Ling Wang, Terence Chi Chun Tam, James Chung Man Ho, David Chi Leung Lam, Mary Sau Man Ip Department of Medicine, the University of Hong Kong, Hong Kong, SAR, People’s Republic of ChinaCorrespondence: Mary Sau Man Ip ...
Kwok WC +5 more
doaj
BackgroundAzithromycin (AZM) effectively reduces asthma exacerbations and enhances bronchial epithelial cell (BEC) antiviral immunity in vitro. However, its clinical impact on different asthma phenotypes is not fully elucidated and differences in ...
Muzhda Ghanizada +14 more
doaj +1 more source
ABSTRACT Background/Objectives Dupilumab is an anti‐interleukin (IL)‐4 receptor (IL‐4Rα) monoclonal antibody used to manage atopic dermatitis (AD). There is a paucity of real‐world Australian data for dupilumab in paediatric AD, especially regarding differences in clinical profiles between age groups.
Paul Sun Woo Kim +7 more
wiley +1 more source
Background The advent of biologics has resulted in major progress in the treatment of severe T2 high asthmatics. There are currently several classes of biologics approved for severe asthma including anti-immunoglobulin E, anti-interleukin-5/interleukin ...
M. Sabbe +3 more
doaj +1 more source
Marco Caminati,1,2 Diego Bagnasco,3 Rachele Vaia,2 Gianenrico Senna11Asthma Center and Allergy Unit, Verona University Hospital, Verona, Italy; 2Department of Medicine, School of Specialization in Allergy and Clinical Immunology, University of Verona ...
Bagnasco D, Senna G, Caminati M, Vaia R
core

